C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making.
Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability.
'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.'
As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage.
'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.'
Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation:
A clear regulatory strategy defined at project start
A tailored data management plan aligned with regulatory goals
A sustainability plan to ensure post-project data availability
Early engagement with regulators led by experienced collaborators
This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making.
Read the full paper, here, and supplementary material, here.
About IHI
The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management.
IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners.
IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit ihi.europa.eu and follow IHI on LinkedIn, Bluesky and Mastodon.
About Critical Path Institute
Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube.
Media Contacts:
Catherine BrettExternal Relations ManagerCatherine.brett@ihi.europa.eu+32 2 541 8214
Roxan Triolo OlivasC-Path Communicationsrolivas@c-path.org+1 520-954-1634
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Borneo Post
2 days ago
- Borneo Post
'No More Drugs 1.2' campaign expands to Keningau, Tenom
Wong (centre) with No More Drugs 1.2 anti-drug campaign committee members. KOTA KINABALU (June 27): Building on the momentum of a successful first wave earlier this year, Lions Clubs International District 308-A2 is launching the second phase of its anti-drug campaign, 'No More Drugs 1.2,' with a renewed focus on youth empowerment and intervention in high-risk communities across Sabah. Earlier this year, 'No More Drugs 1.0' reached over 8,000 participants across Kota Kinabalu, Sandakan and Tawau. The campaign drew widespread engagement through personal testimonies, film screenings and youth forums that sparked heartfelt conversations about the dangers of substance abuse. The upcoming phase will target Kota Kinabalu, Tenom, and notably Keningau — a district identified as a drug activity hotspot. Organising chairperson Nelson Wong said the campaign is driven by the same spirit of unity and hope, with a goal to reach at least 6,000 people. 'This is more than just a campaign — it's a promise to our youth and to the future of Sabah,' said Wong. 'We are deeply committed to addressing the root causes of drug abuse, and we believe in empowering young people with the strength, awareness, and knowledge to choose a healthier, more meaningful path forward.' The screening tour will begin on July 16 at St Michael's in Kota Kinabalu, before moving to Keningau the following day with visits to schools including SJK (C) Yuk Yin, SJK (C) Yuk Kong and SMJK Ken Hwa. A public screening will also be held that evening at SJK (C) Yuk Yin. On July 18, the campaign will reach Tenom through a full-day programme involving several schools, such as SM Chung Hwa, SJK (C) Chung Hwa, and Tenom Tshung Tsin Secondary School. The tour concludes on July 19 with screenings at SM Tshung Tsin, Yue Min in Penampang, and Holy Seal at City Mall, Kota Kinabalu. Beyond film screenings, the campaign will feature youth-focused forums, creative workshops and public engagement activities, supported by local authorities, schools and NGOs. Free counselling services and information on rehabilitation referrals will also be provided at each location. The first phase was widely praised for its grassroots approach, drawing participation from students, teachers and civic leaders, while fostering honest conversations about substance abuse. Lions Clubs International District 308-A2 also extended its gratitude to Second Vice District Governor-Elect Alyssa Lim, former organising chairlady, and her dedicated committee, whose leadership laid the foundation for the campaign's early success. Like its predecessor, 'No More Drugs 1.2' reinforces the powerful message that when young people say no to drugs, they are saying yes to their dreams and to a brighter, healthier future.
Malaysian Reserve
16-06-2025
- Malaysian Reserve
C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making. Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability. 'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.' As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage. 'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.' Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation: A clear regulatory strategy defined at project start A tailored data management plan aligned with regulatory goals A sustainability plan to ensure post-project data availability Early engagement with regulators led by experienced collaborators This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making. Read the full paper, here, and supplementary material, here. About IHI The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners. IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit and follow IHI on LinkedIn, Bluesky and Mastodon. About Critical Path Institute Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube. Media Contacts: Catherine BrettExternal Relations 2 541 8214 Roxan Triolo OlivasC-Path Communicationsrolivas@ 520-954-1634
The Star
01-06-2025
- The Star
Selangor schools to rep Malaysia in regional challenge
TWO schools in Selangor will represent Malaysia at the upcoming AIA Healthiest Schools (AHS) Regional Awards in Da Nang, Vietnam, where they will compete with winners from other nations for prizes totalling US$100,000 (RM424,500). SJK (C) Hwa Lien and SMK Saujana Utama, the national-level primary and secondary champions, will compete alongside winning schools from Indonesia, Thailand, Hong Kong, Australia, Vietnam, Sri Lanka and the Philippines in the regional round of the competition next month. During the AHS Awards ceremony at a hotel in Kuala Lumpur on May 22, SJK (C) Hwa Lien and SMK Saujana Utama received US$10,000 (RM42,450) each for coming out on top in their respective categories of the AHS national-level competition. The awards ceremony celebrated the achievements of 18 primary and secondary schools, recognising their innovative and impactful efforts in promoting student well-being and driving meaningful change within school communities. The winning schools were selected based on project scope and execution, level of engagement with teachers, students and the wider community, overall impact as well as long-term sustainability. At this year's ceremony, which marked the culmination of the second edition of the AHS Competition – a key highlight of the AHS programme – primary and secondary schools received prize money totalling US$100,000 (RM424,500). Held from October last year to March this year, the competition received over 60 entries from government, private and international schools across Malaysia. SJK (C) Hwa Lien, a small island school located on Pulau Ketam, was awarded the top prize for its My School, My Home 2.0 initiative. Congratulations: (Left) Chee and Education Ministry daily school management division senior deputy director Abidin Marjan (sixth and seventh from right) presenting the award to SMK Saujana Utama principal Noor Hayati Embong (centre), project coordinator Hamidah Mukhtar (far right) and teachers. (Right) Nine primary schools were honoured for promoting health and well-being. Designed to address mental health challenges stemming from digital stress, social isolation and language barriers among students, the school introduced inclusive modules focusing on emotional well-being, cultural celebration, physical activity, and language support. The initiative successfully fostered a more connected and resilient student body with the support of parents, the Orang Asli community and neighbouring schools. The second, third and fourth place winners in the primary school category were SK Jalan Empat in Selangor, and SK Oran and SK Kuala Perlis in Perlis, respectively. SJK (C) Pui Ying in Selangor, SK Padang Temu in Melaka, SJK (C) Lawan Kuda Baru in Perak, SJK (C) Han Chiang in Penang and SK Changkat Jawi in Perlis received the Highly Commended Award. In the secondary school category, SMK Saujana Utama in Sungai Buloh clinched first place for Canscape, a creative art-therapy programme under its Terapi Seni Ekspresi mental health initiative, which saw students using recycled tin cans as canvases to express their emotions, turning a simple and low-cost artistic outlet into a powerful tool for emotional regulation. The initiative helped reduce stress and negative behaviours such as vandalism while promoting emotional awareness and empathy. SMK Kuala Jenderis and SMK Kampung Baru Kerteh in Terengganu, and SMK Bukit Baru in Melaka came in second, third and fourth place, respectively, in the secondary school category. SMK (P) Treacher Methodist in Perak, SMK Telok Gadong in Selangor, Sayfol International School in Kuala Lumpur, SMK Paya Rumput in Melaka and SMK Kijal in Terengganu were all presented with the Highly Commended Award. Each of the second, third and fourth prize winners in both the primary and secondary school categories took home US$7,500 (RM31,838), while recipients of the Highly Commended Award received a cash prize of US$3,500 (RM14,858) each. AIA Malaysia chief marketing officer Chee Foong Wai said the AHS programme is part of the company's aim to nurture a culture of health and well-being from an early age. 'We believe real change can start in the classroom. In just two years, what began as a simple vision has made progressive strides. The programme has sparked creativity and passion and empowered the next generation to take charge of their physical, mental and environmental well-being. 'We're incredibly encouraged by the response to this year's competition, which saw twice as many entries compared to last year. It's a positive sign that the momentum is growing – with more schools taking proactive steps to create healthier and happier learning environments for their students,' she said during the awards ceremony. Thanking its partners, she said AIA was proud to celebrate the remarkable efforts of children and educators who are driving real change and making a difference in their schools. Endorsed by the Education Ministry, the AHS programme, launched in 2023, is designed to empower schools to promote healthy eating, active lifestyles, mental well-being and sustainability among students aged five to 16. The programme provides free multilingual teaching resources in English, Bahasa Malaysia and Mandarin, as well as hands-on teacher workshops to equip teachers to effectively introduce health and well-being concepts in the classrooms. Schools interested in registering for the AHS programme can find more information at where teaching resources are also available. Entries for the third edition of the AHS competition can be submitted from October this year.
